These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
210 related items for PubMed ID: 16104902
1. Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study. Malone S, Perry G, Segal R, Dahrouge S, Crook J. BJU Int; 2005 Sep; 96(4):514-20. PubMed ID: 16104902 [Abstract] [Full Text] [Related]
2. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Bruchovsky N, Klotz L, Crook J, Goldenberg SL. Cancer; 2007 Mar 01; 109(5):858-67. PubMed ID: 17265527 [Abstract] [Full Text] [Related]
3. Mature results of the Ottawa phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcome. Malone S, Perry G, Eapen L, Segal R, Gallant V, Dahrouge S, Crook J, Spaans JN. Int J Radiat Oncol Biol Phys; 2007 Jul 01; 68(3):699-706. PubMed ID: 17379438 [Abstract] [Full Text] [Related]
4. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer. Yoon FH, Gardner SL, Danjoux C, Morton G, Cheung P, Choo R. J Urol; 2008 Oct 01; 180(4):1438-43; discussion 1443-4. PubMed ID: 18710743 [Abstract] [Full Text] [Related]
5. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience. Pether M, Goldenberg SL, Bhagirath K, Gleave M. Can J Urol; 2003 Apr 01; 10(2):1809-14. PubMed ID: 12773232 [Abstract] [Full Text] [Related]
6. Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters. Bruchovsky N, Klotz L, Crook J, Malone S, Ludgate C, Morris WJ, Gleave ME, Goldenberg SL. Cancer; 2006 Jul 15; 107(2):389-95. PubMed ID: 16783817 [Abstract] [Full Text] [Related]
8. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study. Spry NA, Galvão DA, Davies R, La Bianca S, Joseph D, Davidson A, Prince R. BJU Int; 2009 Sep 15; 104(6):806-12. PubMed ID: 19281463 [Abstract] [Full Text] [Related]
16. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer. Fujii Y, Yonese J, Kawakami S, Yamamoto S, Okubo Y, Fukui I. BJU Int; 2008 May 15; 101(9):1096-100. PubMed ID: 18190637 [Abstract] [Full Text] [Related]